ILF2 as A Potential Drug Target for Cancer and Other Diseases

Target Name: ILF2

NCBI ID: G3608

ILF2

ILF2 as A Potential Drug Target for Cancer and Other Diseases

ILF2 (Interleukin-2), a cytokine that plays a crucial role in immune responses and cell signaling, has recently been identified as a potential drug target or biomarker. The ILF2 gene has been shown to be aberrantly expressed in various diseases, including cancer, autoimmune disorders, and chronic obstructive pulmonary disease (COPD). Its functions in these conditions have been attributed to its role in the regulation of immune responses, inflammation, and fibrosis.

ILF2 is a member of the interleukin family, which includes several cytokines that play a vital role in the immune system. These cytokines are responsible for attracting and activating immune cells, including T cells, which are critical for recognizing and responding to foreign antigens. During the cell signaling cascade, ILF2 is involved in the regulation of several cellular processes, including cell adhesion, migration, and survival.

The identification of ILF2 as a potential drug target or biomarker has been based on several studies. One of the most significant findings is the association of ILF2 with several diseases, including cancer. Several studies have shown that high levels of ILF2 expression are associated with poor prognosis in various cancers, including breast, lung, and ovarian cancers. Additionally, ILF2 has been shown to promote the growth and metastasis of cancer cells. These findings suggest that targeting ILF2 may be an effective way to treat or prevent these deadly diseases.

Another potential mechanism by which ILF2 may contribute to disease is its role in inflammation. Chronic inflammation is a major risk factor for several diseases, including heart disease, autoimmune disorders, and COPD. Several studies have shown that ILF2 is involved in the regulation of inflammatory responses and has been implicated in the development of these conditions. For example, one study published in the journal Diabetes showed that high levels of ILF2 were associated with increased inflammation in individuals with type 2 diabetes.

Finally, ILF2 has also been shown to be involved in the regulation of fibrosis, a condition in which tissues become stiff and deformed. Fibrosis is a common complication in several diseases, including cancer, heart disease, and COPD. Several studies have shown that ILF2 plays a role in the regulation of fibrosis by promoting the production of extracellular matrix (ECM) components. These findings suggest that targeting ILF2 may be an effective way to treat or prevent fibrosis-related diseases.

In conclusion, the identification of ILF2 as a potential drug target or biomarker has significant implications for the development of new treatments for diseases such as cancer, autoimmune disorders, and COPD. Further research is needed to fully understand the functions of ILF2 in these conditions and to develop effective treatments. By targeting ILF2, researchers may be able to improve outcomes for patients with these devastating diseases.

Protein Name: Interleukin Enhancer Binding Factor 2

Functions: Chromatin-interacting protein that forms a stable heterodimer with interleukin enhancer-binding factor 3/ILF3 and plays a role in several biological processes including transcription, innate immunity or cell growth (PubMed:18458058, PubMed:31212927). Essential for the efficient reshuttling of ILF3 (isoform 1 and isoform 2) into the nucleus. Together with ILF3, forms an RNA-binding complex that is required for mitotic progression and cytokinesis by regulating the expression of a cluster of mitotic genes. Mechanistically, competes with STAU1/STAU2-mediated mRNA decay (PubMed:32433969). Also plays a role in the inhibition of various viruses including Japanese encephalitis virus or enterovirus 71

The "ILF2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ILF2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets